Viridian Therapeutics, Inc./DE Adjustments to Additional Paid in Capital, Other
Viridian Therapeutics, Inc./DE (VRDN) had Adjustments to Additional Paid in Capital, Other of $8.80 million as of 2015-02-26, per its 10-Q filed 2016-10-26.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2017-03-24
- Viridian Therapeutics, Inc./DE adjustments to additional paid in capital, other for fiscal 2014 was $300.00K.
| Period end | Adjustments to Additional Paid in Capital, Other | Adjustments to Additional Paid in Capital, Other as first filed | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|
| 2015-02-26 | $8.80M 10-Q · filed 2016-10-26 | ||
| 2015-02-20 | $8.70M 10-K · filed 2017-03-24 | $8.80M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $300.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |